- Home
- ILPT vs NKTR Comparison
ILPT vs NKTR Comparison
Compare ILPT & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- NKTR
- Stock Information
- Founded
- ILPT 2017
- NKTR 1990
- Country
- ILPT United States
- NKTR United States
- Employees
- ILPT N/A
- NKTR N/A
- Industry
- ILPT Real Estate Investment Trusts
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- ILPT Real Estate
- NKTR Health Care
- Exchange
- ILPT Nasdaq
- NKTR Nasdaq
- Market Cap
- ILPT 232.8M
- NKTR 247.9M
- IPO Year
- ILPT 2018
- NKTR 1994
- Fundamental
- Price
- ILPT $3.73
- NKTR $0.90
- Analyst Decision
- ILPT Buy
- NKTR Strong Buy
- Analyst Count
- ILPT 2
- NKTR 5
- Target Price
- ILPT $10.00
- NKTR $4.50
- AVG Volume (30 Days)
- ILPT 359.3K
- NKTR 1.5M
- Earning Date
- ILPT 02-18-2025
- NKTR 03-03-2025
- Dividend Yield
- ILPT 1.10%
- NKTR N/A
- EPS Growth
- ILPT N/A
- NKTR N/A
- EPS
- ILPT N/A
- NKTR N/A
- Revenue
- ILPT $440,696,000.00
- NKTR $93,137,000.00
- Revenue This Year
- ILPT N/A
- NKTR $12.85
- Revenue Next Year
- ILPT $6.87
- NKTR N/A
- P/E Ratio
- ILPT N/A
- NKTR N/A
- Revenue Growth
- ILPT 1.36
- NKTR 5.53
- 52 Week Low
- ILPT $3.15
- NKTR $0.50
- 52 Week High
- ILPT $5.45
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- ILPT 58.67
- NKTR 40.16
- Support Level
- ILPT $3.50
- NKTR $0.87
- Resistance Level
- ILPT $3.75
- NKTR $0.94
- Average True Range (ATR)
- ILPT 0.14
- NKTR 0.09
- MACD
- ILPT 0.02
- NKTR -0.01
- Stochastic Oscillator
- ILPT 95.00
- NKTR 15.63
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.